Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Ocular Therapeutix Inc (NASDAQ: OCUL) closed at $8.43 up 0.96% from its previous closing price of $8.35. In other words, the price has increased by $0.96 from its previous closing price. On the day, 0.6 million shares were traded. OCUL stock price reached its highest trading level at $8.62 during the session, while it also had its lowest trading level at $8.2.
Ratios:
For a deeper understanding of Ocular Therapeutix Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.55 and its Current Ratio is at 16.64. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, TD Cowen on June 20, 2024, Upgraded its rating to Buy and sets its target price to $11 from $7 previously.
On February 09, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $15.BofA Securities initiated its Buy rating on February 09, 2024, with a $15 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 23 ’24 when Nayak Sanjay sold 1,832 shares for $9.02 per share. The transaction valued at 16,525 led to the insider holds 176,194 shares of the business.
Dugel Pravin sold 20,880 shares of OCUL for $188,338 on Aug 23 ’24. The insider now owns 812,473 shares after completing the transaction at $9.02 per share. On Aug 27 ’24, another insider, RABIA OZDEN, who serves as the Officer of the company, bought 18,333 shares for $9.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1314422528 and an Enterprise Value of 917144064. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.51 while its Price-to-Book (P/B) ratio in mrq is 3.47. Its current Enterprise Value per Revenue stands at 15.011 whereas that against EBITDA is -8.282.
Stock Price History:
Over the past 52 weeks, OCUL has reached a high of $11.31, while it has fallen to a 52-week low of $2.00. The 50-Day Moving Average of the stock is 6.47%, while the 200-Day Moving Average is calculated to be 31.05%.
Shares Statistics:
For the past three months, OCUL has traded an average of 1.72M shares per day and 778380 over the past ten days. A total of 155.92M shares are outstanding, with a floating share count of 135.51M. Insiders hold about 13.09% of the company’s shares, while institutions hold 76.73% stake in the company. Shares short for OCUL as of 1723680000 were 18774495 with a Short Ratio of 10.89, compared to 1721001600 on 20376130. Therefore, it implies a Short% of Shares Outstanding of 18774495 and a Short% of Float of 12.0900005.
